Stryker Corporation $SYK Stock Holdings Trimmed by Boston Trust Walden Corp

Key Points

• Boston Trust Walden Corp reduced its holdings in Stryker Corporation by 3.5%, owning 309,835 shares after selling 11,133 shares in the 2nd quarter.
• Stryker Corporation reported a quarterly revenue of $6.02 billion for the latest quarter, which was above analysts' expectations, and it achieved an earnings per share of $3.13.
• The company announced a quarterly dividend of $0.84 per share, representing an annualized yield of 0.9%, with a payout ratio of 44.50%.

Boston Trust Walden Corp lowered its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 3.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 309,835 shares of the medical technology company's stock after selling 11,133 shares during the period. Stryker makes up 0.9% of Boston Trust Walden Corp's holdings, making the stock its 22nd largest position. Boston Trust Walden Corp owned approximately 0.08% of Stryker worth $122,580,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Consolidated Portfolio Review Corp raised its stake in shares of Stryker by 4.2% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company's stock worth $256,000 after buying an additional 26 shares in the last quarter. Sunflower Bank N.A. raised its stake in shares of Stryker by 4.0% in the 2nd quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company's stock worth $275,000 after buying an additional 27 shares in the last quarter. Pitti Group Wealth Management LLC raised its stake in shares of Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company's stock worth $341,000 after buying an additional 27 shares in the last quarter. Sachetta LLC raised its stake in shares of Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock worth $29,000 after buying an additional 27 shares in the last quarter. Finally, Comprehensive Financial Consultants Institutional Inc. raised its stake in shares of Stryker by 0.6% in the 2nd quarter. Comprehensive Financial Consultants Institutional Inc. now owns 4,546 shares of the medical technology company's stock worth $1,799,000 after buying an additional 28 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Stock Up 0.1%

Shares of Stryker stock opened at $364.95 on Tuesday. The stock's fifty day moving average is $379.93 and its 200-day moving average is $378.91. The firm has a market capitalization of $139.52 billion, a PE ratio of 48.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.94. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the previous year, the company posted $2.81 earnings per share. Stryker's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's payout ratio is currently 44.50%.

Insiders Place Their Bets

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.20% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on SYK shares. UBS Group set a $408.00 price objective on Stryker in a research note on Monday. Truist Financial set a $415.00 price objective on Stryker and gave the stock a "hold" rating in a research note on Monday, August 4th. Needham & Company LLC boosted their target price on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Rothschild & Co Redburn initiated coverage on Stryker in a research report on Thursday, September 18th. They set a "neutral" rating and a $420.00 target price on the stock. Finally, Rothschild Redb raised Stryker to a "hold" rating in a research report on Thursday, September 18th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $432.14.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.